Vor Biopharma (NYSE:VOR) Shares Down 2.7% – Time to Sell?

Vor Biopharma Inc. (NYSE:VOR) fell 2.7% on Friday . The stock traded as low as $0.95 and last traded at $1.08. 356,891 shares were traded during trading, a decline of 42% from the average session volume of 618,261 shares. The stock had previously closed at $1.11.

Analyst Upgrades and Downgrades

VOR has been the subject of a number of recent research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a report on Tuesday, December 10th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Vor Biopharma in a research note on Monday, December 9th. Robert W. Baird cut their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $11.36.

Vor Biopharma Price Performance

The company’s 50-day moving average price is $1.33 and its two-hundred day moving average price is $1.01. The company has a market capitalization of $74.17 million, a price-to-earnings ratio of -0.65 and a beta of -0.45.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP increased its stake in shares of Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after acquiring an additional 25,930 shares in the last quarter. Trustees of Columbia University in the City of New York bought a new stake in Vor Biopharma in the fourth quarter valued at $102,000. RA Capital Management L.P. boosted its position in shares of Vor Biopharma by 74.3% during the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Northern Trust Corp grew its stake in shares of Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after buying an additional 44,252 shares during the period. Finally, Lynx1 Capital Management LP bought a new stake in Vor Biopharma in the 4th quarter valued at about $707,000. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.